2013 Q2 Form 10-Q Financial Statement
#000110465913041980 Filed on May 15, 2013
Income Statement
Concept | 2013 Q2 | 2013 Q1 | 2012 Q1 |
---|---|---|---|
Revenue | $281.0K | $147.0K | $208.0K |
YoY Change | 208.79% | -29.33% | |
Cost Of Revenue | $0.00 | ||
YoY Change | |||
Gross Profit | $100.0K | ||
YoY Change | |||
Gross Profit Margin | 68.03% | ||
Selling, General & Admin | $12.20M | $13.53M | $2.728M |
YoY Change | 165.22% | 396.08% | 60.47% |
% of Gross Profit | 13533.0% | ||
Research & Development | $3.500M | $4.522M | $5.358M |
YoY Change | -25.53% | -15.6% | -28.09% |
% of Gross Profit | 4522.0% | ||
Depreciation & Amortization | $100.0K | $162.0K | $225.0K |
YoY Change | -35.9% | -28.0% | 12.5% |
% of Gross Profit | 162.0% | ||
Operating Expenses | $15.70M | $18.06M | $8.086M |
YoY Change | 68.82% | 123.29% | 8.52% |
Operating Profit | -$17.91M | -$7.878M | |
YoY Change | 127.32% | -14.35% | |
Interest Expense | -$10.70M | $727.0K | $962.0K |
YoY Change | 970.0% | -24.43% | -420.67% |
% of Operating Profit | |||
Other Income/Expense, Net | $0.00 | -$506.0K | -$1.399M |
YoY Change | -100.0% | -63.83% | 599.5% |
Pretax Income | -$27.40M | -$18.40M | -$9.300M |
YoY Change | 174.0% | 97.85% | -4.12% |
Income Tax | $0.00 | $0.00 | $0.00 |
% Of Pretax Income | |||
Net Earnings | -$27.36M | -$18.41M | -$9.277M |
YoY Change | 173.21% | 98.49% | -16.04% |
Net Earnings / Revenue | -9735.59% | -12526.53% | -4460.1% |
Basic Earnings Per Share | |||
Diluted Earnings Per Share | -$886.7K | -$595.5K | -$715.4K |
COMMON SHARES | |||
Basic Shares Outstanding | 30.99M shares | 30.89M shares | 1.676M shares |
Diluted Shares Outstanding |
Balance Sheet
Concept | 2013 Q2 | 2013 Q1 | 2012 Q1 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $102.6M | $69.90M | $37.40M |
YoY Change | 34.29% | 86.9% | |
Cash & Equivalents | $33.90M | $18.91M | $15.87M |
Short-Term Investments | $68.70M | $51.00M | $21.50M |
Other Short-Term Assets | $2.300M | $1.000M | $1.000M |
YoY Change | 64.29% | 0.0% | |
Inventory | $4.300M | $3.113M | |
Prepaid Expenses | |||
Receivables | $500.0K | $1.650M | |
Other Receivables | $800.0K | $600.0K | |
Total Short-Term Assets | $110.6M | $76.33M | $38.42M |
YoY Change | 42.15% | 98.69% | |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $2.200M | $1.687M | $1.200M |
YoY Change | 91.97% | 40.58% | |
Goodwill | |||
YoY Change | |||
Intangibles | $626.0K | ||
YoY Change | |||
Long-Term Investments | $16.10M | ||
YoY Change | |||
Other Assets | $2.500M | $363.0K | $2.700M |
YoY Change | 1150.0% | -86.56% | |
Total Long-Term Assets | $21.40M | $2.729M | $4.785M |
YoY Change | 890.74% | -42.97% | |
TOTAL ASSETS | |||
Total Short-Term Assets | $110.6M | $76.33M | $38.42M |
Total Long-Term Assets | $21.40M | $2.729M | $4.785M |
Total Assets | $132.0M | $79.06M | $43.20M |
YoY Change | 65.07% | 83.0% | |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $2.200M | $3.700M | $9.300M |
YoY Change | -76.09% | -60.22% | |
Accrued Expenses | $9.600M | $7.240M | $1.200M |
YoY Change | 500.0% | 503.33% | |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | $0.00 | $12.10M | $9.200M |
YoY Change | -100.0% | 31.52% | |
Total Short-Term Liabilities | $16.00M | $27.01M | $19.91M |
YoY Change | -26.88% | 35.64% | |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $59.10M | $8.000M | $19.90M |
YoY Change | 245.61% | -59.8% | |
Other Long-Term Liabilities | $21.00M | $1.860M | $3.100M |
YoY Change | 600.0% | -40.0% | |
Total Long-Term Liabilities | $80.10M | $1.860M | $23.00M |
YoY Change | 298.51% | -91.91% | |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $16.00M | $27.01M | $19.91M |
Total Long-Term Liabilities | $80.10M | $1.860M | $23.00M |
Total Liabilities | $96.10M | $37.79M | $42.93M |
YoY Change | 128.89% | -11.97% | |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$104.7M | ||
YoY Change | |||
Common Stock | $31.00K | ||
YoY Change | |||
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $35.90M | $41.27M | $274.0K |
YoY Change | |||
Total Liabilities & Shareholders Equity | $132.0M | $79.06M | $43.20M |
YoY Change | 65.0% | 83.0% |
Cashflow Statement
Concept | 2013 Q2 | 2013 Q1 | 2012 Q1 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$27.36M | -$18.41M | -$9.277M |
YoY Change | 173.21% | 98.49% | -16.04% |
Depreciation, Depletion And Amortization | $100.0K | $162.0K | $225.0K |
YoY Change | -35.9% | -28.0% | 12.5% |
Cash From Operating Activities | -$15.80M | -$17.22M | -$10.07M |
YoY Change | 62.89% | 71.07% | 2.73% |
INVESTING ACTIVITIES | |||
Capital Expenditures | -$600.0K | $372.0K | $40.00K |
YoY Change | 200.0% | 830.0% | -120.0% |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | -$33.80M | -$2.800M | -$21.50M |
YoY Change | 338.96% | -86.98% | 290.91% |
Cash From Investing Activities | -$34.50M | -$3.149M | -$21.55M |
YoY Change | 348.05% | -85.39% | 278.12% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | $1.936M | $49.00K | |
YoY Change | 3851.02% | ||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 65.20M | -$1.021M | -$1.057M |
YoY Change | 33.33% | -3.41% | -108.39% |
NET CHANGE | |||
Cash From Operating Activities | -15.80M | -$17.22M | -$10.07M |
Cash From Investing Activities | -34.50M | -$3.149M | -$21.55M |
Cash From Financing Activities | 65.20M | -$1.021M | -$1.057M |
Net Change In Cash | 14.90M | -$21.39M | -$32.68M |
YoY Change | -52.7% | -34.53% | 1026.83% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$15.80M | -$17.22M | -$10.07M |
Capital Expenditures | -$600.0K | $372.0K | $40.00K |
Free Cash Flow | -$15.20M | -$17.60M | -$10.11M |
YoY Change | 60.0% | 74.07% | 5.29% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2012Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
40302000 | USD |
CY2012Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
48206000 | USD |
CY2013Q1 | us-gaap |
Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
|
P10Y | |
CY2012Q4 | us-gaap |
Interest Receivable Current
InterestReceivableCurrent
|
664000 | USD |
CY2012Q4 | us-gaap |
Inventory Net
InventoryNet
|
1152000 | USD |
CY2012Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
994000 | USD |
CY2012Q4 | us-gaap |
Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
|
144000 | USD |
CY2012Q4 | us-gaap |
Assets Current
AssetsCurrent
|
91462000 | USD |
CY2013Q1 | us-gaap |
Assets Current
AssetsCurrent
|
76332000 | USD |
CY2012Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1421000 | USD |
CY2012Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
683000 | USD |
CY2012Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
334000 | USD |
CY2012Q4 | us-gaap |
Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
|
89000 | USD |
CY2012Q4 | us-gaap |
Assets
Assets
|
93989000 | USD |
CY2013Q1 | us-gaap |
Assets
Assets
|
79061000 | USD |
CY2012Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
10666000 | USD |
CY2012Q4 | us-gaap |
Secured Debt Current
SecuredDebtCurrent
|
11809000 | USD |
CY2012Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
22983000 | USD |
CY2013Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
27008000 | USD |
CY2012Q4 | us-gaap |
Secured Long Term Debt
SecuredLongTermDebt
|
11088000 | USD |
CY2012Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
1788000 | USD |
CY2012Q4 | us-gaap |
Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
|
251000 | USD |
CY2012Q4 | us-gaap |
Liabilities
Liabilities
|
36419000 | USD |
CY2013Q1 | us-gaap |
Liabilities
Liabilities
|
37789000 | USD |
CY2012Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
31000 | USD |
CY2012Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
143851000 | USD |
CY2012Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-57000 | USD |
CY2012Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-86255000 | USD |
CY2012Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
57570000 | USD |
CY2013Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
41272000 | USD |
CY2012Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
93989000 | USD |
CY2013Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
79061000 | USD |
CY2013Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2012Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2013Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
130000000 | shares |
CY2012Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
130000000 | shares |
CY2013Q1 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
2292000 | USD |
CY2013Q1 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
1666000 | USD |
CY2012Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
2292000 | USD |
CY2013Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
30894666 | shares |
CY2012Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
30621869 | shares |
CY2013Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
30894666 | shares |
CY2012Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
30621869 | shares |
CY2012Q1 | us-gaap |
Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
|
-328000 | USD |
CY2012Q1 | us-gaap |
Marketable Securities Unrealized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments
|
-8000 | USD |
CY2012Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
225000 | USD |
CY2012Q1 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
83000 | USD |
CY2012Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
52000 | USD |
CY2013Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
1650000 | USD |
CY2013Q1 | us-gaap |
Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
|
8000 | USD |
CY2013Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
1961000 | USD |
CY2012Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-10068000 | USD |
CY2012Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
158000 | USD |
CY2012Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-1254000 | USD |
CY2012Q1 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
208000 | USD |
CY2012Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
5358000 | USD |
CY2012Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
2728000 | USD |
CY2012Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
8086000 | USD |
CY2012Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-7878000 | USD |
CY2012Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
19000 | USD |
CY2012Q1 | us-gaap |
Interest Expense
InterestExpense
|
962000 | USD |
CY2012Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-456000 | USD |
CY2012Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1399000 | USD |
CY2012Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9277000 | USD |
CY2012Q1 | us-gaap |
Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
|
858000 | USD |
CY2012Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-10135000 | USD |
CY2013Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-18414000 | USD |
CY2013Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-18414000 | USD |
CY2013Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-506000 | USD |
CY2013Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-17908000 | USD |
CY2013Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
18055000 | USD |
CY2013Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.60 | |
CY2013Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
30875424 | shares |
CY2012Q1 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
-17000 | USD |
CY2013Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-17223000 | USD |
CY2012Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
21806000 | USD |
CY2012Q1 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
293000 | USD |
CY2012Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
40000 | USD |
CY2012Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-21553000 | USD |
CY2013Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-3149000 | USD |
CY2012Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
49000 | USD |
CY2012Q1 | us-gaap |
Repayments Of Secured Debt
RepaymentsOfSecuredDebt
|
437000 | USD |
CY2012Q1 | us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
669000 | USD |
CY2012Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-1057000 | USD |
CY2013Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-1021000 | USD |
CY2012Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-32678000 | USD |
CY2013Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-21393000 | USD |
CY2012Q1 | us-gaap |
Interest Paid
InterestPaid
|
688000 | USD |
CY2011Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
48544000 | USD |
CY2012Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
15866000 | USD |
CY2013Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
18909000 | USD |
CY2013Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1. Organization and Business</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Supernus Pharmaceuticals, Inc. (the Company) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company has two proprietary products and several proprietary product candidates in clinical development that address the epilepsy and attention deficit hyperactivity disorder markets.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">The Company is currently focused on the commercialization of Oxtellar XR and the anticipated commercialization of Trokendi XR (formerly known as SPN-538). Oxtellar XR received final approval from the Food and Drug Administration (FDA) on October 19, 2012 and the Company began the commercial launch of this product on February 4, 2013.  In addition, Trokendi XR received tentative approval from the FDA on June 25, 2012.  The Company anticipates the commercial launch of this product in the third quarter of 2013 pending receipt of final approval from the FDA.</font></p> </div> | |
CY2013Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
5184000 | USD |
CY2013Q1 | dei |
Entity Registrant Name
EntityRegistrantName
|
SUPERNUS PHARMACEUTICALS INC | |
CY2013Q1 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001356576 | |
CY2013Q1 | dei |
Document Type
DocumentType
|
10-Q | |
CY2013Q1 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2013-03-31 | |
CY2013Q1 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2013Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
CY2013Q1 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2013Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Smaller Reporting Company | |
CY2013Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
30985416 | shares |
CY2013Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2013 | |
CY2013Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
CY2013Q1 | supn |
Number Of Proprietary Products In Clinical Development
NumberOfProprietaryProductsInClinicalDevelopment
|
2 | item |
CY2013Q1 | us-gaap |
Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
|
0 | USD |
CY2012Q1 | us-gaap |
Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
|
150000 | USD |
CY2012Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
48259000 | USD |
CY2012Q4 | us-gaap |
Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
|
1000 | USD |
CY2012Q4 | us-gaap |
Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
|
54000 | USD |
CY2012Q4 | us-gaap |
Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
|
48206000 | USD |
CY2013Q1 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
51072000 | USD |
CY2013Q1 | us-gaap |
Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
|
0 | USD |
CY2013Q1 | us-gaap |
Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
|
89000 | USD |
CY2013Q1 | us-gaap |
Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
|
50983000 | USD |
CY2013Q1 | us-gaap |
Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
|
2985000 | USD |
CY2012Q4 | us-gaap |
Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
|
1152000 | USD |
CY2013Q1 | supn |
Sales Return Period
SalesReturnPeriod
|
P1Y | |
CY2013Q1 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
128000 | USD |
CY2013Q1 | us-gaap |
Inventory Net
InventoryNet
|
3113000 | USD |
CY2013Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
6871000 | USD |
CY2012Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
6499000 | USD |
CY2012Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
5078000 | USD |
CY2013Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1687000 | USD |
CY2012Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
1609000 | USD |
CY2012Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
57000 | USD |
CY2013Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
57000 | USD |
CY2013Q1 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
626000 | USD |
CY2013Q1 | supn |
Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
|
2898000 | USD |
CY2013Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
2238000 | USD |
CY2013Q1 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
187000 | USD |
CY2013Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1917000 | USD |
CY2013Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
7240000 | USD |
CY2012Q4 | supn |
Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
|
3335000 | USD |
CY2012Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
2492000 | USD |
CY2012Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
213000 | USD |
CY2012Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1820000 | USD |
CY2012Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
7860000 | USD |
CY2012Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
8000 | USD |
CY2012Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-9269000 | USD |
CY2013Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
363000 | USD |
CY2013Q1 | us-gaap |
Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
|
53000 | USD |
CY2013Q1 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
10903000 | USD |
CY2013Q1 | us-gaap |
Secured Debt Current
SecuredDebtCurrent
|
12137000 | USD |
CY2013Q1 | us-gaap |
Secured Long Term Debt
SecuredLongTermDebt
|
7975000 | USD |
CY2013Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-18446000 | USD |
CY2012Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
1676442 | shares |
CY2013Q1 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
50983000 | USD |
CY2013Q1 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
1650000 | USD |
CY2013Q1 | us-gaap |
Interest Receivable Current
InterestReceivableCurrent
|
672000 | USD |
CY2013Q1 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
1860000 | USD |
CY2013Q1 | us-gaap |
Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
|
172000 | USD |
CY2013Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
31000 | USD |
CY2013Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
145999000 | USD |
CY2013Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-89000 | USD |
CY2013Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-104669000 | USD |
CY2013Q1 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
147000 | USD |
CY2013Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
861000 | USD |
CY2013Q1 | us-gaap |
Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
|
144000 | USD |
CY2013Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
4522000 | USD |
CY2013Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
13533000 | USD |
CY2013Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
52000 | USD |
CY2013Q1 | us-gaap |
Interest Expense
InterestExpense
|
727000 | USD |
CY2013Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
169000 | USD |
CY2012Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-6.05 | |
CY2013Q1 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-32000. | USD |
CY2013Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-32000 | USD |
CY2012Q1 | us-gaap |
Depreciation
Depreciation
|
167000 | USD |
CY2013Q1 | us-gaap |
Depreciation
Depreciation
|
106000 | USD |
CY2012Q1 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
8000 | USD |
CY2013Q1 | us-gaap |
Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
|
79000 | USD |
CY2013Q1 | us-gaap |
Marketable Securities Unrealized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments
|
32000 | USD |
CY2013Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
162000 | USD |
CY2013Q1 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
83000 | USD |
CY2013Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
337000 | USD |
CY2013Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-133000 | USD |
CY2013Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
238000 | USD |
CY2013Q1 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
44000 | USD |
CY2013Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
15643000 | USD |
CY2013Q1 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
12866000 | USD |
CY2013Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
372000 | USD |
CY2013Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
1936000 | USD |
CY2013Q1 | us-gaap |
Repayments Of Secured Debt
RepaymentsOfSecuredDebt
|
2832000 | USD |
CY2013Q1 | us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
125000 | USD |
CY2013Q1 | us-gaap |
Interest Paid
InterestPaid
|
610000 | USD |
CY2012Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
52000 | USD |
CY2013Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
337000 | USD |
CY2012 | us-gaap |
Prior Period Reclassification Adjustment
PriorPeriodReclassificationAdjustment
|
279000 | USD |
CY2013Q1 | supn |
Finite Lived Intangible Assets Estimated Annual Aggregate Amortization Expense
FiniteLivedIntangibleAssetsEstimatedAnnualAggregateAmortizationExpense
|
229000 | USD |
CY2012Q4 | us-gaap |
Inventory Adjustments
InventoryAdjustments
|
0 | USD |
CY2013Q1 | us-gaap |
Inventory Adjustments
InventoryAdjustments
|
0 | USD |
CY2013Q1 | supn |
Inventory Work In Process And Raw Materials Net Of Reserves For Which Tentative Approval Received From Fda
InventoryWorkInProcessAndRawMaterialsNetOfReservesForWhichTentativeApprovalReceivedFromFDA
|
2000000 | USD |